-
C.
Proud
(2009)
mTORC1 signalling and mRNA translation.
Biochemical Society transactions, 37 Pt 1
-
S.
Wullschleger,
R.
Loewith,
M.
Hall
(2006)
TOR Signaling in Growth and Metabolism
Cell, 124
-
(2005)
Fused bicyclic mTOR inhibitors. US2007112005 (OSI Pharmaceuticals Inc
-
Yu-Yun
Chang,
G.
Juhász,
Pankuri
Goraksha-Hicks,
A.
Arsham,
D.
Mallin,
Laura
Muller,
T.
Neufeld
(2009)
Nutrient-dependent regulation of autophagy through the target of rapamycin pathway.
Biochemical Society transactions, 37 Pt 1
-
D.
Guertin,
D.
Sabatini
(2007)
Defining the role of mTOR in cancer.
Cancer cell, 12 1
-
G.
Chiang,
R.
Abraham
(2007)
Targeting the mTOR signaling network in cancer.
Trends in molecular medicine, 13 10
-
S.
Faivre,
G.
Kroemer,
E.
Raymond
(2006)
Current development of mTOR inhibitors as anticancer agents
Nature Reviews Drug Discovery, 5
-
J.
Engelman
(2009)
Targeting PI3K signalling in cancer: opportunities, challenges and limitations
Nature Reviews Cancer, 9
-
(1406)
Mol Cancer Ther Molecular Cancer Therapeutics American Association for Cancer Research. mct.aacrjournals.org Downloaded from Published OnlineFirst June
-
M.
Feldman,
Beth
Apsel,
A.
Uotila,
R.
Loewith,
Z.
Knight,
D.
Ruggero,
K.
Shokat
(2009)
Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2
PLoS Biology, 7
-
R.
Loewith,
E.
Jacinto,
S.
Wullschleger,
A.
Lorberg,
J.
Crespo,
D.
Bonenfant,
W.
Oppliger,
P.
Jenoe,
M.
Hall
(2002)
Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control.
Molecular cell, 10 3
-
Beverly
Falcón,
S.
Barr,
P.
Gokhale,
Jeyling
Chou,
J.
Fogarty,
P.
Depeille,
M.
Miglarese,
D.
Epstein,
D.
McDonald
(2011)
Reduced VEGF production, angiogenesis, and vascular regrowth contribute to the antitumor properties of dual mTORC1/mTORC2 inhibitors.
Cancer research, 71 5
-
R.
Abraham,
Christina
Eng
(2008)
Mammalian target of rapamycin as a therapeutic target in oncology.
Expert opinion on therapeutic targets, 12 2
-
S.
Bhagwat,
A.
Crew
(2010)
Novel inhibitors of mTORC1 and mTORC2.
Current opinion in investigational drugs, 11 6
-
K.
Jessen,
Shunyou
Wang,
L.
Kessler,
Xin
Guo,
Jeff
Kucharski,
J.
Staunton,
L.
Lan,
M.
Elia,
J.
Stewart,
J.
Brown,
Lian-Sheng
Li,
Katrina
Chan,
Michael
Martin,
Pingda
Ren,
C.
Rommel,
Yi
Liu
(2009)
Abstract B148: INK128 is a potent and selective TORC1/2 inhibitor with broad oral antitumor activity
Molecular Cancer Therapeutics, 8
-
E.
Jacinto,
R.
Loewith,
A.
Schmidt,
Shuo
Lin,
M.
Rüegg,
A.
Hall,
M.
Hall
(2004)
Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive
Nature Cell Biology, 6
-
H.
Hosoi,
M.
Dilling,
T.
Shikata,
Linda
Liu,
L.
Shu,
R.
Ashmun,
G.
Germain,
R.
Abraham,
P.
Houghton
(1999)
Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells.
Cancer research, 59 4
-
J.
García-Martínez,
Jennifer
Moran,
R.
Clarke,
A.
Gray,
S.
Cosulich,
C.
Chresta,
D.
Alessi
(2009)
Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR)
Biochemical Journal, 421
-
K.
O'reilly,
F.
Rojo,
Q.
She,
D.
Solit,
G.
Mills,
Debra
Smith,
H.
Lane,
F.
Hofmann,
D.
Hicklin,
D.
Ludwig,
J.
Baselga,
N.
Rosen
(2006)
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt.
Cancer research, 66 3
-
K.
Jessen,
Shunyou
Wang,
Xin
Guo,
L.
Kessler,
Jeff
Kucharski,
J.
Staunton,
L.
Lan,
M.
Elia,
J.
Stewart,
J.
Brown,
Lian-Sheng
Li,
Katrina
Chan,
Michael
Martin,
Pingda
Ren,
C.
Rommel,
Yi
Liu
(2010)
Abstract 1668: Pharmacodynamic biomarker development for INK128, a potent and selective inhibitor of TORC1/2 for the treatment of cancer
Cancer Research, 70
-
J.
Dancey
(2010)
mTOR signaling and drug development in cancer
Nature Reviews Clinical Oncology, 7
-
Q.
Ji,
M.
Mulvihill,
Maryland
Rosenfeld-Franklin,
A.
Cooke,
Lixin
Feng,
G.
Mak,
M.
O’Connor,
Yan
Yao,
Caroline
Pirritt,
E.
Buck,
A.
Eyzaguirre,
L.
Arnold,
N.
Gibson,
J.
Pachter
(2007)
A novel, potent, and selective insulin-like growth factor-I receptor kinase inhibitor blocks insulin-like growth factor-I receptor signaling in vitro and inhibits insulin-like growth factor-I receptor–dependent tumor growth in vivo
Molecular Cancer Therapeutics, 6
-
(2011)
Author Manuscript Published OnlineFirst
-
R.
Abraham
(1996)
Phosphatidylinositol 3-kinase related kinases.
Current opinion in immunology, 8 3
-
N.
Carayol,
Eliza
Vakana,
A.
Sassano,
S.
Kaur,
Dennis
Goussetis,
H.
Glaser,
B.
Druker,
N.
Donato,
J.
Altman,
S.
Barr,
L.
Platanias
(2010)
Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells
Proceedings of the National Academy of Sciences, 107
-
H.
Lane,
M.
Breuleux
(2009)
Optimal targeting of the mTORC1 kinase in human cancer.
Current opinion in cell biology, 21 2
-
T.
Cloughesy,
K.
Yoshimoto,
P.
Nghiemphu,
K.
Brown,
Julie
Dang,
Shaojun
Zhu,
Teli
Hsueh,
Yinan
Chen,
Wei
Wang,
D.
Youngkin,
L.
Liau,
N.
Martin,
Donald
Becker,
M.
Bergsneider,
A.
Lai,
R.
Green,
Tom
Oglesby,
Michael
Koleto,
Jeff
Trent,
S.
Horvath,
P.
Mischel,
I.
Mellinghoff,
C.
Sawyers
(2008)
Antitumor Activity of Rapamycin in a Phase I Trial for Patients with Recurrent PTEN-Deficient Glioblastoma
PLoS Medicine, 5
-
C.
Chresta,
B.
Davies,
Ian
Hickson,
Tom
Harding,
S.
Cosulich,
S.
Critchlow,
J.
Vincent,
Rebecca
Ellston,
Darren
Jones,
P.
Sini,
D.
James,
Z.
Howard,
Phillippa
Dudley,
G.
Hughes,
Lisa
Smith,
Sharon
Maguire,
M.
Hummersone,
Karine
Malagu,
K.
Menear,
R.
Jenkins,
Matt
Jacobsen,
G.
Smith,
S.
Guichard,
M.
Pass
(2010)
AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity.
Cancer research, 70 1
-
Carson
Thoreen,
S.
Kang,
J.
Chang,
Qingsong
Liu,
Jianming
Zhang,
Yi
Gao,
L.
Reichling,
Taebo
Sim,
D.
Sabatini,
N.
Gray
(2009)
An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1*
Journal of Biological Chemistry, 284
-
I.
Simera,
D.
Altman,
D.
Moher,
K.
Schulz,
J.
Hoey
(2008)
Guidelines for Reporting Health Research: The EQUATOR Network's Survey of Guideline Authors
PLoS Medicine, 5
-
F.
Meric-Bernstam,
A.
González-Angulo
(2009)
Targeting the mTOR signaling network for cancer therapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 13
-
A.
Choo,
Sang-Oh
Yoon,
Sang
Kim,
Philippe
Roux,
J.
Blenis
(2008)
Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation
Proceedings of the National Academy of Sciences, 105
-
D.
Sarbassov,
D.
Guertin,
Siraj
Ali,
D.
Sabatini
(2005)
Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex
Science, 307
-
(2006)
J Biol Chem
-
Ker
Yu,
C.
Shi,
L.
Toral‐Barza,
J.
Lucas,
Boris
Shor,
Jae
Kim,
Wei-Guo
Zhang,
R.
Mahoney,
Christine
Gaydos,
L.
Tardio,
Sung
Kim,
R.
Conant,
K.
Curran,
Joshua
Kaplan,
J.
Verheijen,
S.
Ayral-Kaloustian,
T.
Mansour,
R.
Abraham,
A.
Zask,
J.
Gibbons
(2010)
Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2.
Cancer research, 70 2
-
D.
Sarbassov,
Siraj
Ali,
Do-Hyung
Kim,
D.
Guertin,
R.
Latek,
H.
Erdjument-Bromage,
P.
Tempst,
D.
Sabatini
(2004)
Rictor, a Novel Binding Partner of mTOR, Defines a Rapamycin-Insensitive and Raptor-Independent Pathway that Regulates the Cytoskeleton
Current Biology, 14
-
K.
Kim,
R.
Mutter,
C.
Cao,
J.
Albert,
M.
Freeman,
D.
Hallahan,
B.
Lu
(2006)
Autophagy for Cancer Therapy through Inhibition of Pro-apoptotic Proteins and Mammalian Target of Rapamycin Signaling*
Journal of Biological Chemistry, 281
-
M.
O’Connor,
A.
Mohan,
Suzanne
Brady,
Christine
Mantis,
P.
Gokhale,
M.
Miglarese,
S.
Barr
(2011)
Abstract 4463: OSI-027, a dual mTORC1/mTORC2 inhibitor, induces autophagy in cancer cells
Cancer Research, 71